Lisata Therapeutics
LSTA
20 hedge funds and large institutions have $2.26M invested in Lisata Therapeutics in 2025 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 4 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
23% more capital invested
Capital invested by funds: $1.84M → $2.26M (+$417K)
0.01% less ownership
Funds ownership: 9.09% → 9.08% (-0.01%)
9% less funds holding
Funds holding: 22 → 20 (-2)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cerity Partners
New York
|
+$29.3K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$17K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.37K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.33K |
| 5 |
Renaissance Technologies
New York
|
+$240 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$16.9K |
| 2 |
Morgan Stanley
New York
|
-$2.99K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.13K |
| 4 |
JP Morgan Chase
New York
|
-$31 |
| 5 |
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors
Boston,
Massachusetts
|
-$5 |
LSTA Hedge Fund Activity: Q2 2025 in Review
20 of the 7,616 institutional investors tracked by Wall St. Rank reported a position in Lisata Therapeutics (LSTA) for Q2 2025, worth a combined $2.26M — up 23% from $1.84M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of LSTA and 2 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 5 added.
The largest buyer was Cerity Partners, opening a new position worth an estimated $29.3K. The largest seller was BML Capital Management, cutting an estimated $16.9K.
- 20 institutional investors held Lisata Therapeutics (LSTA) as of Q2 2025, down from 22 in Q1 2025.
- Funds reported $2.26M of Lisata Therapeutics stock for Q2 2025, up 23% quarter-over-quarter.
- 2 funds opened new Lisata Therapeutics positions in Q2 2025 and 4 closed out, a net change of -2 holders.
- The largest Lisata Therapeutics buyer in Q2 2025 was Cerity Partners, an estimated $29.3K added.
- The largest Lisata Therapeutics seller in Q2 2025 was BML Capital Management, an estimated $16.9K sold.
Based on aggregated 13F filings for Q2 2025.